Paul Marotta
Overview
Explore the profile of Paul Marotta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
940
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alghamdi W, Lotfy K, Weernink C, Alsolami E, Jevnikar A, Luke P, et al.
BMC Gastroenterol
. 2022 Jan;
22(1):34.
PMID: 35078405
Background: Transplantation offers the best survival for patients with end stage organ disease. Transplant of hepatitis C virus (HCV) nucleic acid test (NAT) positive organs into negative recipients is a...
2.
Aziz S, Sey M, Marotta P, Driman D, Parfitt J, Teriaky A, et al.
Transplant Proc
. 2021 Jul;
53(6):1975-1979.
PMID: 34272052
Background: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation is a major cause of morbidity and mortality. To date, there is no widely accepted pathologic assessment tool to predict HCC...
3.
Meyers B, Vogel A, Marotta P, Kavan P, Kamboj L, Pan J, et al.
Can J Gastroenterol Hepatol
. 2021 Mar;
2021:8811018.
PMID: 33681090
Lenvatinib is an oral multikinase inhibitor indicated for the first-line treatment of unresectable hepatocellular carcinoma (uHCC). In the Phase III REFLECT trial, lenvatinib was noninferior in the primary endpoint of...
4.
Swain M, Ramji A, Patel K, Sebastiani G, Shaheen A, Tam E, et al.
CMAJ Open
. 2020 Jun;
8(2):E429-E436.
PMID: 32518095
Background: Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) account for a growing proportion of liver disease cases, and there is a need to better understand future disease burden....
5.
Al-Judaibi B, Alqalami I, Sey M, Qumosani K, Howes N, Sinclair L, et al.
Transplant Proc
. 2019 Nov;
51(10):3330-3337.
PMID: 31732200
Background And Aims: Frailty is associated with increased morbidity and mortality, and this is tightly linked to liver decompensation and increased complication rates among liver transplant (LT) candidates. The aim...
6.
Al Draiweesh S, Ma C, Alkhattabi M, McDonald C, Nguyen T, Beaton M, et al.
Inflamm Bowel Dis
. 2019 Oct;
26(6):949-959.
PMID: 31665288
Background: Patients with inflammatory bowel disease (IBD) post-liver transplant (LT) may have bowel inflammation requiring biologic therapy. We aimed to evaluate the safety of combination biologic and antirejection therapy in...
7.
Xu Q, McAlister V, Leckie S, House A, Skaro A, Marotta P
Am J Transplant
. 2019 Aug;
20(1):282-288.
PMID: 31419065
Angiotensin II type I receptor (AT1R) agonistic autoantibodies (AT1R-AA) are detrimental to kidney transplantation. Early studies suggested a similar negative effect in primary liver transplantation. Here, we studied AT1R-AA in...
8.
The role of imaging in determining prognosis for primary sclerosing cholangitis: A systematic review
Segal D, Marotta P, Mosli M, Zou G, Feagan B, Al-Judaibi B
Saudi J Gastroenterol
. 2019 May;
25(3):152-158.
PMID: 31044745
Background/aims: Primary sclerosing cholangitis (PSC) is a chronic, progressive, fibrotic bile duct disease. Resultant complications include infection, progressive liver disease and cancer. While diagnosis relies extensively on imaging, the role...
9.
Al-Judaibi B, Thomas B, Wong P, Benmassaoud A, Chen J, Dokus M, et al.
Ann Hepatol
. 2018 May;
17(3):437-443.
PMID: 29735784
Introduction And Aim: Sofosbuvir (SOF)-based regimen has been shown to have high efficacy even in patients with decompensated cirrhosis. Treated patients may experience various degrees of hepatic recovery ranging from...
10.
Feld J, Ramji A, Shafran S, Willems B, Marotta P, Huchet E, et al.
Clin Infect Dis
. 2017 May;
65(1):13-19.
PMID: 28535298
Background: Patients chronically infected with genotype 3 hepatitis C virus (HCV) have faster disease progression and are less responsive to current direct-acting antiviral regimens than patients infected with other genotypes....